Category:
Announcements
The Center for Drug Design (CDD) in collaboration with the University of Minnesota Technology Commercialization team, and our industry Licensee, TOPIX Pharmaceuticals, Inc., held a mini-symposium where attendees engaged in a scientific discussion on ProteXidine's journey from lab to market. ProteXidine is a proprietary biomimetic decoy molecule enhances skin's natural ability to mitigate damage caused by UV exposure and Reactive Oxygen Species (ROS). Ongoing scientific research continues to reveal promising new applications. ProteXidine®: The Intersection of Science, Technology, and Skin-Aging.
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning.
Center for Drug Design (College of Pharmacy, University of Minnesota) has signed an agreement to collaborate with medical imaging startup RetiSpec to commercialize the technology for early detection of Alzheimer’s disease.
Compounds developed in Robert Vince’s University of Minnesota lab to combat the HIV virus made the University more than $600 million dollars.
The Twin Cities Business Magazine discusses the cyanide antidote invented by Profs. Vince, Patterson, and Nagasawa. The USPTO has issued a new patent to the U of M Regents on September 12, 2017.
Prof Swati More, and Prof Robert Vince (Director of the Center for Drug Design), have discovered a potential new drug that works as an antidote to acetaminophen poisoning.
Prof Robert Vince has been awarded the Antonin Holy Memorial Award from the International Society for Antiviral Research (ISAR)
How many millions of lives has Dr. Robert Vince saved? It’s hard to put an exact number on it, but millions certainly, if not a good deal more.